 Dithi Banerjee
Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Tract Infections | 5 | 2024 | 82 | 1.570 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2024 | 27 | 1.530 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2024 | 50 | 1.500 |
Why?
| | Influenza, Human | 3 | 2022 | 62 | 1.440 |
Why?
| | Influenza B virus | 2 | 2019 | 22 | 1.310 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2019 | 13 | 1.310 |
Why?
| | Influenza A virus | 2 | 2019 | 20 | 1.310 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2022 | 38 | 1.200 |
Why?
| | Nasopharynx | 4 | 2021 | 25 | 1.090 |
Why?
| | Virus Diseases | 3 | 2024 | 16 | 1.080 |
Why?
| | Pharyngitis | 1 | 2020 | 15 | 0.720 |
Why?
| | Streptococcal Infections | 1 | 2020 | 19 | 0.720 |
Why?
| | Humans | 20 | 2024 | 6929 | 0.710 |
Why?
| | Cryptococcus neoformans | 2 | 2016 | 2 | 0.690 |
Why?
| | Child | 14 | 2024 | 3348 | 0.680 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 3 | 0.570 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 3 | 0.570 |
Why?
| | Glucose | 1 | 2016 | 23 | 0.560 |
Why?
| | Antibodies, Viral | 4 | 2022 | 47 | 0.480 |
Why?
| | Nucleotides | 1 | 2014 | 2 | 0.480 |
Why?
| | Amphotericin B | 1 | 2014 | 2 | 0.480 |
Why?
| | Antifungal Agents | 1 | 2014 | 13 | 0.470 |
Why?
| | Adult | 7 | 2024 | 1199 | 0.470 |
Why?
| | Infant | 10 | 2024 | 1449 | 0.440 |
Why?
| | Enterovirus Infections | 2 | 2023 | 37 | 0.400 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 151 | 0.380 |
Why?
| | Young Adult | 6 | 2024 | 641 | 0.360 |
Why?
| | Picornaviridae Infections | 2 | 2021 | 21 | 0.350 |
Why?
| | Prospective Studies | 5 | 2024 | 547 | 0.350 |
Why?
| | Adolescent | 8 | 2024 | 2183 | 0.330 |
Why?
| | Child, Preschool | 7 | 2024 | 1562 | 0.330 |
Why?
| | Middle Aged | 5 | 2021 | 645 | 0.320 |
Why?
| | Female | 9 | 2024 | 3534 | 0.320 |
Why?
| | Male | 8 | 2024 | 3367 | 0.300 |
Why?
| | Spike Glycoprotein, Coronavirus | 3 | 2021 | 19 | 0.290 |
Why?
| | Cryptococcosis | 2 | 2016 | 2 | 0.260 |
Why?
| | Aged | 3 | 2021 | 411 | 0.250 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 8 | 0.240 |
Why?
| | Retrospective Studies | 2 | 2019 | 1337 | 0.240 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 33 | 0.230 |
Why?
| | Schools | 1 | 2024 | 56 | 0.230 |
Why?
| | Parechovirus | 2 | 2021 | 20 | 0.230 |
Why?
| | Enterovirus D, Human | 1 | 2023 | 25 | 0.220 |
Why?
| | Coronavirus | 1 | 2022 | 2 | 0.220 |
Why?
| | Aged, 80 and over | 2 | 2021 | 168 | 0.220 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2022 | 9 | 0.210 |
Why?
| | Paramyxoviridae Infections | 1 | 2022 | 12 | 0.210 |
Why?
| | Viral Vaccines | 1 | 2022 | 10 | 0.210 |
Why?
| | Saliva | 1 | 2021 | 10 | 0.200 |
Why?
| | Specimen Handling | 1 | 2021 | 17 | 0.200 |
Why?
| | Nasal Mucosa | 1 | 2021 | 8 | 0.200 |
Why?
| | Immunity, Humoral | 1 | 2021 | 14 | 0.200 |
Why?
| | Central Nervous System Infections | 1 | 2021 | 5 | 0.200 |
Why?
| | Enterobacteriaceae | 1 | 2021 | 7 | 0.190 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2021 | 11 | 0.190 |
Why?
| | Enterovirus | 1 | 2021 | 12 | 0.190 |
Why?
| | Cephalosporins | 1 | 2021 | 15 | 0.190 |
Why?
| | Asthma | 1 | 2023 | 152 | 0.190 |
Why?
| | Quebec | 1 | 2020 | 4 | 0.190 |
Why?
| | Pharynx | 1 | 2020 | 7 | 0.180 |
Why?
| | Canada | 1 | 2020 | 34 | 0.180 |
Why?
| | RNA, Messenger | 2 | 2021 | 115 | 0.180 |
Why?
| | Streptococcus pyogenes | 1 | 2020 | 13 | 0.180 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 3 | 0.180 |
Why?
| | Rhinovirus | 1 | 2020 | 11 | 0.180 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 50 | 0.170 |
Why?
| | Communicable Diseases, Emerging | 1 | 2019 | 3 | 0.170 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2019 | 6 | 0.170 |
Why?
| | Microbial Sensitivity Tests | 2 | 2021 | 33 | 0.160 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 243 | 0.160 |
Why?
| | Seasons | 3 | 2024 | 35 | 0.160 |
Why?
| | Missouri | 3 | 2024 | 77 | 0.150 |
Why?
| | Ribosomes | 1 | 2016 | 1 | 0.140 |
Why?
| | Ribosomal Proteins | 1 | 2016 | 4 | 0.140 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2016 | 3 | 0.140 |
Why?
| | RNA Stability | 1 | 2016 | 4 | 0.140 |
Why?
| | Fungal Proteins | 1 | 2016 | 10 | 0.140 |
Why?
| | Infant, Newborn | 3 | 2024 | 826 | 0.120 |
Why?
| | Aspergillus fumigatus | 1 | 2014 | 1 | 0.120 |
Why?
| | Flucytosine | 1 | 2014 | 1 | 0.120 |
Why?
| | Candida albicans | 1 | 2014 | 4 | 0.120 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 6 | 0.120 |
Why?
| | HIV Infections | 1 | 2014 | 52 | 0.110 |
Why?
| | Kansas | 2 | 2023 | 43 | 0.100 |
Why?
| | Prevalence | 2 | 2023 | 150 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2021 | 148 | 0.090 |
Why?
| | Students | 1 | 2024 | 34 | 0.060 |
Why?
| | Research Design | 1 | 2024 | 63 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 63 | 0.060 |
Why?
| | Cohort Studies | 1 | 2024 | 281 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 2023 | 29 | 0.060 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 9 | 0.050 |
Why?
| | Vaccination | 1 | 2022 | 70 | 0.050 |
Why?
| | Hospitalization | 1 | 2024 | 209 | 0.050 |
Why?
| | Viral Load | 1 | 2021 | 14 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2021 | 18 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2021 | 16 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2021 | 31 | 0.050 |
Why?
| | Epitope Mapping | 1 | 2021 | 7 | 0.050 |
Why?
| | Antibody Specificity | 1 | 2021 | 8 | 0.050 |
Why?
| | Cross Reactions | 1 | 2021 | 8 | 0.050 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 8 | 0.050 |
Why?
| | Epitopes | 1 | 2021 | 20 | 0.050 |
Why?
| | United States | 1 | 2024 | 670 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2021 | 15 | 0.050 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2021 | 34 | 0.050 |
Why?
| | Transcriptome | 1 | 2021 | 59 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 31 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2021 | 216 | 0.050 |
Why?
| | Biomarkers | 1 | 2021 | 132 | 0.050 |
Why?
| | Age Factors | 1 | 2021 | 211 | 0.050 |
Why?
| | Mouth | 1 | 2020 | 3 | 0.050 |
Why?
| | DNA, Viral | 1 | 2020 | 13 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 23 | 0.050 |
Why?
| | Postoperative Care | 1 | 2020 | 29 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2020 | 119 | 0.040 |
Why?
| | Risk Assessment | 1 | 2020 | 136 | 0.040 |
Why?
| | Prognosis | 1 | 2020 | 216 | 0.040 |
Why?
| | Phylogeny | 1 | 2019 | 23 | 0.040 |
Why?
| | Fever | 1 | 2019 | 27 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 116 | 0.040 |
Why?
| | Genotype | 1 | 2019 | 408 | 0.040 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|